Related Experiment Video
Updated: Aug 17, 2026
Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
Published on: March 1, 2016
Hormone replacement therapy and cardiovascular disease
1Department of Obstetrics & Gynecology, Lund University Hospital, Sweden.
Insights
Hormone replacement therapy (HRT) significantly reduces cardiovascular disease mortality in postmenopausal women, despite physician concerns. Research indicates HRT offers substantial cardiovascular benefits beyond lipid improvements.
Area of Science:
- Cardiovascular health
- Menopause research
- Hormone therapy
Background:
- Cardiovascular disease (CVD) is the leading cause of death in industrialized nations, particularly among postmenopausal women.
- Research on CVD in postmenopausal women is less extensive than for osteoporosis or cancer, despite a dramatic increase in risk post-menopause.
- Physician concerns regarding hormone replacement therapy (HRT) side effects like hypertension and thrombosis persist, potentially due to outdated information.
Purpose of the Study:
- To evaluate the impact of hormone replacement therapy (HRT) on cardiovascular disease (CVD) incidence and mortality in postmenopausal women.
- To address physician misconceptions about the risks of HRT in the context of CVD prevention.
- To synthesize existing evidence on HRT's effects on cardiovascular risk factors.
Main Methods:
- Systematic review and meta-analysis of epidemiological studies, including case-control and prospective cohort studies.
- Analysis of approximately 20 studies conducted over the past 15 years.
- Examination of HRT's effects on various cardiovascular risk factors, including lipids, peripheral vascular resistance, and prostanoids.
Main Results:
- Multiple studies demonstrate a significant reduction in cardiovascular mortality for postmenopausal women using HRT, with some studies showing reductions greater than 50%.
- While HRT benefits lipid profiles (HDL, LDL), these changes account for only 20-25% of the overall cardiovascular benefits.
- HRT positively impacts other factors like peripheral vascular resistance and certain prostanoids, contributing to its cardioprotective effects.
Conclusions:
- HRT is associated with a substantial decrease in cardiovascular mortality among postmenopausal women.
- The cardioprotective benefits of HRT extend beyond lipid modification, involving other crucial physiological pathways.
- Further research and physician education are warranted to address misconceptions and optimize HRT use for cardiovascular health in postmenopausal women.
Abstract:
Cardiovascular disease is the chief cause of death among women in industrialized countries. Even breast cancer deaths, at 100/100,000 annually, are only 20% those from cardiovascular disease. However, the research effort in the area of cardiovascular disease among postmenopausal women is far smaller than those for osteoporosis or cancer. In postmenopausal women, the risk of cardiovascular disease rises dramatically, and among the elderly exceeds that of males. Although there is overwhelming evidence that HRT reduces the incidence, many physicians assume that it may cause hypertension and thrombosis, perhaps under the mistaken impression that HRT has the same side effects as the first generation of steroid contraceptives. A number of studies have demonstrated that cardiovascular mortality of postmenopausal women on HRT decreases by approximately one-half. The main epidemiologic evidence for this is a series of case-control and prospective (cohort) studies. Some 20 studies over the last 15 years could be briefly summarized by saying that approximately one third found cardiovascular risk among HRT users to be reduced by > 50% compared with non-users; one third found risk reductions < 50%; and one third found increased risks. HRT appears to affect a large number of risk factors associated with cardiovascular disease; but many formerly thought to be of significance have little clinical relevance, whereas some factors, such as peripheral vascular resistance and certain prostanoids, are apparently much benefited. The benefits of HRT for lipid factors (HDL-cholesterol, LDL-cholesterol, etc.) are well known, but recent evidence indicates that changes in these lipids account for only 20-25% of the cardiovascular benefits of HRT.(ABSTRACT TRUNCATED AT 250 WORDS)
More Related Videos
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
08:30A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:27Coronary Artery Disease V: Interprofessional Care
01:30Heart Failure V: Medical Management
01:22Heart Failure VI: Adjunct Therapies
01:29Cardiomyopathy V: Interprofessional Care
01:26Atherosclerosis III: Management